Worm.com

Guide to Spyware and AntiVirus Information

You are currently browsing the Worm.com weblog archives for the day Friday, June 13th, 2008.

 

Sponsors

Archive for June 13th, 2008

HD on the way

Verizon announced that in early July it will start rolling out new high-definition channels, the first sign of progress since it told FiOS subscribers to expect 150 HD channels by the end of 2008.

Verizon is going to add 60 new channels, 25 of them HD, first. The HD channels will include Lifetime HD, Animal Planet HD, TLC HD, The Science Channel HD, and the Smithsonian Channel HD, as well as five more HD channels from movie networks Starz and Showtime.

Dead bird hotline

Suffolk County has set up a hotline for residents to report certain types of dead birds that may be infected with the West Nile Virus.

Call (631) 787-2200 between 9 a.m. and 4 p.m. Monday through Friday. Leave a message to report birds discovered in the evening and early morning hours.

A Duck in Mexico

Want a better job in a warmer, more adventurous climate? Just join the Long Island Ducks and bat a .362 average.

Ray Navarrate, an outfielder in the Islip-based Atlantic League baseball team, was just signed by Olmecas de Tabasco, a AAA team in the Mexico League.

It’s too bad for the Ducks, because Navarrate was the league’s home run leader.

Copyright 2008 Dolan Media Newswires
Provided by ProQuest Information and Learning Company. All rights Reserved.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

INTERNET BUSINESS NEWS-(C)1995-2008 M2 COMMUNICATIONS LTD

On 12 June, AdaptiveMobile, http://www.adaptivemobile.com, a mobile security protection provider, appealed to mobile operators all over the world to follow the example set by the US in the fight against child pornography.

The company announced that three of America’s largest Internet service providers - Verizon, Sprint and Time Warner Cable - have committed USD1m to help block access to child pornography sites and bulletin boards, after US government pressure for control and protection on the Internet.

AdaptiveMobile commented that the child pornography problem is immoral, illegal and needs to be stopped. The number of mobile subscribers who access the Internet via their phones is rising all the time, resulting in a major growth of illegal content. Therefore it is vital that efforts to combat the growing presence of illegal and exploitative child content are extended into the mobile environment.

According to AdaptiveMobile, its parental controls are already being used by a number of mobile phone operators worldwide, ensuring a safe

mobile environment for teenagers and children. Its Policy Control Framework software protects subscribers against illegal or inappropriate content and unsolicited or unauthorised communications. It is applicable on all mobile services (WAP, SMS, MMS, email) and all forms of access (Mobile, WiFi, WiMax) and media including mobile internet, text, images, music, voice and video. Protection from the ever present threat of mobile viruses, malware, inappropriate content, unsolicited communications and spam is also offered by the company.

No pricing details have been released.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2008 M2 Communications Ltd.
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

TRUSTe, the recognized authority on
privacy best practices on the Internet, today announced Sandi Hardmeier
will join TRUSTe as an Online Compliance Researcher. Ms. Hardmeier is a
recognized and widely sought after industry expert in the field of malware
and malvertizing and their impact on consumer privacy and security. She
will play a key role in TRUSTe’s development of improved network monitoring
strategies while providing customers with expert insight and
recommendations to combat existing and emerging Web threats such as
spyware, computer viruses, and other types of malware.

“Sandi has been studying malware since 2000, and has watched its
metamorphosis from simplistic, easy to remove adware into the sophisticated
crime-motivated products we see today,” said Fran Maier, executive director
of TRUSTe. “Sandi will help us build our expertise in the important
intersection between online trust, privacy and security.”

Sandi has been a Microsoft Most Valued Professional (MVP) since 1999,
specializing in Internet Explorer and Internet Security as it pertains to
business and consumers. She also has an array of published work and is the
author of www.msmvps.com/spywaresucks (a Web site dedicated to teaching
Internet users about the latest risks to their online safety and how to
stay safe when surfing the Web); www.ie-vista.com (dedicated to providing
technical support to users of IE7 and IE8); and
http://inetexplorer.mvps.org (dedicated to providing technical support to
users of IE6 and earlier).

About TRUSTe

TRUSTe helps millions of consumers identify trustworthy online
organizations through its Web Privacy Seal, Email Privacy Seal and Trusted
Download Programs. TRUSTe ensures online privacy and protects confidential
user information on more than 2,400 Web sites and many of the most highly
trafficked, including Yahoo, AOL, Microsoft, Disney, eBay, Intuit, and
Facebook. Independent research shows that when a TRUSTe web seal is
present, visitors and customers are more likely to share personal
information, register at higher rates and spend more money. To learn more
about internet privacy visit www.truste.org .

Media Contact:
Carolyn Hodge
TRUSTe
(415) 520-3415
Email Contact

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

WASHINGTON — Democrat Barack Obama’s campaign said Thursday that Michelle Obama never used the word “whitey” in a speech from the church pulpit as it launched a Web site to debunk rumors about him and his wife.

The rumor that Michelle Obama railed against “whitey” in a diatribe at Chicago’s Trinity United Church of Christ has circulated on conservative Republican blogs for weeks and was repeated by radio talk show host Rush Limbaugh. The rumor included claims of a videotape of the speech that would be used to bring down Obama’s candidacy this fall.

“No such tape exists,” the campaign responds on the site, www.fightthesmears.com. “Michelle Obama has not spoken from the pulpit at Trinity and has not used that word.”

The site is a response to the realities of a brave new world, where information travels 24 hours a day on blogs and voters are increasingly turning to the Internet for information. It’s a particular problem for Obama, a relative newcomer to national politics who is still unknown to many voters and has been the target of persistent misinformation campaigns online.

In another sign of the campaign moving into the general election race, the Democratic National Committee’s spokeswoman said Thursday its political and field operations are relocating to Chicago, where Obama’s campaign is based. While other departments will remain in Washington, it’s an effort to streamline the campaign and party efforts in one strategy instead of the overlapping efforts of past presidential elections.

E-mails about Obama rank No. 2 on the list of “Hottest Urban Legends” on snopes.com, an Internet rumor-debunking site, behind e- mail greeting cards that could expose computers to viruses.

Michelle Obama has often been the target of conservative attacks, prompting Obama to demand his rivals “lay off my wife.” Much of the criticism came from her comment that her husband’s campaign has made her proud of her country “for the first time,” a remark that inspired a Tennessee Republican Party Web video questioning her patriotism.

There also have been more insulting attacks and not limited to the Internet.

Fox News Channel referred to Michelle Obama as “Obama’s baby mama” in a graphic on Wednesday, using the slang description of a woman who has a baby outside of a romantic relationship or marriage. Fox anchor E.D. Hill also referred to it as a “terrorist fist jab” when the Obamas bumped knuckles on the night he clinched the nomination. Hill has apologized.

The Obamas recently resigned from Trinity, where the Rev. Jeremiah Wright was the longtime pastor. Wright came under fire for sermons in which he cursed America and accused the government of conspiring against blacks. Video of the sermons spread quickly on the Internet and threatened great damage to Obama’s campaign.

Other false claims about the Illinois senator — that he’s secretly a Muslim who refuses to say the Pledge of Allegiance and is intent on destroying America — spread widely during the primary campaign, and Obama made it a habit of telling audiences to respond to e-mail rumors to set the record straight.

Barack Obama bristled when he was asked about the “whitey” rumor on his campaign plane last week, saying it was nonsense that shouldn’t be repeated in questioning by a mainstream reporter.

“It is a destructive aspect of our politics right now,” Obama told his traveling press corps. “And simply because something appears in an e-mail, that should lend it no more credence than if you heard it on the corner. And you know, presumably the job of the press is to not go around and spread scurrilous rumors like this until there’s actually anything, one iota of substance or evidence that would substantiate it.”

At the same time, his campaign was preparing the debunking Web site in a recognition that refusing to address rumors only perpetuates them.

The site explains that Obama is “a committed Christian” who never attended a radical madrassa during his childhood in Indonesia. With chain e-mails falsely claiming Obama was sworn into the Senate on the Quran, the holy book of Islam, the Web site includes a photo of him taking his oath of office on the family Bible.

It shows C-SPAN video of Obama leading the Pledge of Allegiance with his hand over his heart as he presided over the Senate on June 21, 2007. It encourages people to send e-mail to friends and “spread the truth.”

“The Obama campaign isn’t going to let dishonest smears spread across the Internet unanswered,” said spokesman Tommy Vietor. “It’s not enough to just know the truth, we have to be proactive and fight back.”

Copyright C 2008 Deseret News Publishing Co.
Provided by ProQuest Information and Learning Company. All rights Reserved.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Olivier Panis agrees that it is somewhat unusual to be considered a rookie after 13 years in Formula 1 - including famously triumphing the Monaco Grand Prix - but as he prepares to make his bow in the iconic Le Mans 24 Hours this weekend, a rookie indeed he is.

Having taken a sabbatical to spend some time with his family after hanging up his F1 helmet at the end of 2006 - thereby bringing the curtain down on a career that took in stints with McLaren-Mercedes, Toyota, BAR-Honda, Ligier and Prost Grand Prix - the Frenchman has clearly caught the racing bug once more, having signed up to compete with Oreca in the Le Mans Series and, of course, sportscar racing’s undisputed jewel in the crown, the legendary ‘24 Heures’.

What’s more, with a podium finish at Spa-Francorchamps - only his third outing in the LMP1 Courage - Panis has …


Read the full article with a Free Trial at MyWire.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

PARIS, June 13 /PRNewswire-FirstCall/ — Abbott announced new data from the open-label extension of the ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS) phase III clinical trial, which showed HUMIRA(R) (adalimumab) reduced the signs and symptoms of ankylosing spondylitis (AS) for up to three years of treatment among 74 percent of patients tested. AS is a type of arthritis that primarily causes inflammation of the spine and the spinal joints. These data were presented at the European League Against Rheumatism (EULAR) annual meeting in Paris.

"There is no cure for ankylosing spondylitis and the goal of therapy is to relieve back and joint pain," said Desiree van der Heijde, M.D., co-lead investigator of ATLAS and Professor of Rheumatology at Leiden University Medical Center, The Netherlands. "Even partial remission of AS can have a considerable positive impact on a patient’s symptoms. These data are reassuring for patients because they demonstrate that adalimumab can be an effective treatment for ankylosing spondylitis."

Three-Year ATLAS Data Summary

ATLAS was a randomized, placebo-controlled, double-blind, Phase III study conducted in the U.S. and Europe. The study involved 315 patients with active AS who had an inadequate response to at least one non-steroidal anti-inflammatory drug (NSAID) or disease modifying anti-rheumatic drug (DMARD). Patients received HUMIRA 40mg subcutaneously or placebo every other week (EOW). Results at 12 and 24 weeks showed HUMIRA patients experienced a statistically significant reduction in signs and symptoms according to the Assessment in SpondyloArthritis International Society (ASAS) measure, or ASAS20 compared to placebo. ASAS20 represents at least a 20 percent improvement in at least three of the four assessments to measure patient improvement and response to therapy. At 24 weeks, all patients were switched to an open-label HUMIRA 40mg EOW dose trial for an additional 236 weeks. Improvement was observed through three years of treatment.

  Efficacy
  --  After three years, 74 percent (174/234) of patients achieved ASAS20.
  --  After three years, 42 percent (97/234) of patients achieved ASAS
      partial remission.

Physicians measure the severity of AS on a scale of 0-100 for level of pain, function, inflammation and a general overall assessment by the patient. Partial remission of the disease is classified as a score of less than 20 on a 0-100 scale in each of those four assessments.

  Safety
  --  The most common adverse experiences occurring in greater than or equal
      to five percent of patients during three years of exposure were
      nasopharyngitis, upper respiratory tract infection and headache.
  --  There were no cases of tuberculosis or demyelinating disorders. There
      was one death caused by malignancy.

  About Ankylosing Spondylitis (AS)

AS is a rheumatic condition that affects young adults, and is more common in men than in women. Ankylosis means "fusion" and spondylitis means "inflammation of the spine." Advanced AS can lead to new bone formation on the spine causing it to fuse in a fixed position. It commonly begins before the age of 35. It is estimated that nearly three million people in Europe and at least half a million people in the United States are affected by AS or a related spondyloarthropathy. However, there are likely more people affected by AS because it is under-recognized and under-diagnosed.

Important Safety Information

Globally, prescribing information varies; refer to the individual country product label for complete information.

Serious infections, sepsis, rare cases of tuberculosis (TB), and opportunistic infections, including fatalities, have been reported with the use of TNF antagonists, including HUMIRA. Many of the serious infections have occurred in patients on concomitant immunosuppressive therapy that, in addition to their underlying disease could predispose them to infections. Patients must be monitored closely for infections, including tuberculosis, before, during and after treatment with HUMIRA. Treatment should not be initiated in patients with active infections until infections are controlled. HUMIRA should not be used by patients with active TB or other severe infections such as sepsis and opportunistic infections. Patients who develop new infections while using HUMIRA should be monitored closely. HUMIRA should be discontinued if a patient develops a new serious infection until infections are controlled. Physicians should exercise caution when considering use of HUMIRA in patients with a history of recurring infection or with underlying conditions that may predispose patients to infections.

TNF-blocking agents have been associated with reactivation of hepatitis B (HBV) in patients who are chronic carriers of the virus. Some cases have been fatal. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating HUMIRA.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

PARIS, June 13 /PRNewswire-FirstCall/ — Seven-year rheumatoid arthritis (RA) data from open-label extension studies show that treatment with Abbott’s HUMIRA(R) (adalimumab) resulted in clinical remission among long-standing RA patients when used in combination with methotrexate (MTX). The percentage of patients achieving clinical remission continued to increase after two or more years of continuous treatment with combination therapy. These data were presented at the European League Against Rheumatism (EULAR) annual meeting in Paris.

The seven-year HUMIRA data are a combined analysis of open-label extensions of the ARMADA, DE019, STAR, DE005 and DE037 trials. The open-label extension period of these studies assessed the measures of efficacy, remission and change over time in the safety profile in patients with long-standing RA treated for up to seven years with 40mg of HUMIRA every other week plus MTX.

"Rheumatoid arthritis is a chronic, progressive disease with no cure and usually requires long-term management for patients, so it is reassuring that HUMIRA has demonstrated up to seven years of efficacy in patients with this disease," said Michael E. Weinblatt, M.D., Brigham and Women’s Hospital, Boston, and lead investigator.

Seven-Year Clinical Data Summary

A total of 1,469 patients with a history of RA who had continued on from randomized, controlled HUMIRA trials were treated with HUMIRA and MTX for greater than or equal to 30 days and up to seven years in open-label extension studies. The average length of exposure to treatment was 47 months.

  The randomized controlled HUMIRA study included:

   *    The ARMADA trial: a Phase III study to evaluate efficacy and safety
        of HUMIRA in patients with moderate to severe RA who had failed at
        least one disease-modifying anti-rheumatic drug (DMARD).
   *    DE019: a Phase III study, which evaluated the efficacy and safety of
        HUMIRA in patients with moderate to severe RA with inadequate
        response to MTX, including assessment of inhibition of radiographic
        progression.
   *    The STAR trial: a Phase III study that evaluated the efficacy and
        safety of HUMIRA when added to a standard treatment regimen for RA
        in patients with inadequate response.
   *    DE005: a Phase I study evaluating the safety and efficacy of HUMIRA
        in combination with methotrexate in methotrexate partial responders.
   *    DE037: a Phase I roll-over study that evaluated the safety,
        pharmacokinetics and early signs of HUMIRA efficacy among RA
        patients in the United States and Japan.

  Efficacy

   *    After six months of therapy, all efficacy measures showed
        significant improvements versus baseline.
   *    At year two, additional improvements were observed in American
        College of Rheumatology (ACR) responses.  ACR responses represent a
        percent improvement in tender joint count, swollen joint count and
        other relevant clinical measures.
   *    Improved response after year one was confirmed by examining
        sustained clinical remission (Disease Activity Score (DAS28) of less
        than 2.6) for at least three consecutive visits; sustained remission
        was achieved in 42 percent of all patients after a mean of 18 +/- 17
        months.  DAS28 is a composite index that includes variables such as
        the number of tender and swollen joints, specific laboratory values
        and other measures of disease activity.

  Safety

   *    The treatment exposure-adjusted rate of serious adverse events
        (SAEs), and serious infections, declined progressively during seven
        years of observation.
   *    Rates and types of SAEs were consistent with randomized controlled
        trials, including the rate of serious infections.  Two patients
        reported tuberculosis, one after three months and another after 13
        months of exposure.

  About Rheumatoid Arthritis

Unlike osteoarthritis, the most common form of arthritis, RA is an autoimmune disease where joints are inflamed, which may lead to damage of the joints’ interior and the surrounding bone. The joints most commonly affected during the beginning of the disease are the smaller joints of the fingers, feet and wrists. The elbows, knees, ankles and hips can be affected, but less often. Although there is no cure for RA, people continue to seek treatments that not only alleviate the pain and inflammation but also slow disease progression, thereby inhibiting the joint damage that can hinder patients from performing daily activities. Five million people worldwide are currently living with RA and most of them are between the ages of 25 and 55.

Important Safety Information

Globally, prescribing information varies; refer to the individual country product label for complete information.

Serious infections, sepsis, rare cases of tuberculosis (TB), and opportunistic infections, including fatalities, have been reported with the use of TNF antagonists, including HUMIRA. Many of the serious infections have occurred in patients on concomitant immunosuppressive therapy that, in addition to their underlying disease could predispose them to infections. Patients must be monitored closely for infections, including tuberculosis, before, during and after treatment with HUMIRA. Treatment should not be initiated in patients with active infections until infections are controlled. HUMIRA should not be used by patients with active TB or other severe infections such as sepsis and opportunistic infections. Patients who develop new infections while using HUMIRA should be monitored closely. HUMIRA should be discontinued if a patient develops a new serious infection until infections are controlled. Physicians should exercise caution when considering use of HUMIRA in patients with a history of recurring infection or with underlying conditions that may predispose patients to infections.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis